APA

Hoekstra C. J., Stroobants S. G., Hoekstra O. S., Vansteenkiste J., Biesma B., Schramel F. J. H. M., van Zandwijk N., van Tinteren H. & Smit E. F. (20031006). The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. : Lung cancer (Amsterdam, Netherlands).

Chicago

Hoekstra C J, Stroobants S G, Hoekstra O S, Vansteenkiste J, Biesma B, Schramel F J H M, van Zandwijk N, van Tinteren H and Smit E F. 20031006. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. : Lung cancer (Amsterdam, Netherlands).

Harvard

Hoekstra C. J., Stroobants S. G., Hoekstra O. S., Vansteenkiste J., Biesma B., Schramel F. J. H. M., van Zandwijk N., van Tinteren H. and Smit E. F. (20031006). The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. : Lung cancer (Amsterdam, Netherlands).

MLA

Hoekstra C J, Stroobants S G, Hoekstra O S, Vansteenkiste J, Biesma B, Schramel F J H M, van Zandwijk N, van Tinteren H and Smit E F. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. : Lung cancer (Amsterdam, Netherlands). 20031006.